Bayer’s pharma sales will “remain stable” through 2026, division chief Stefan Oelrich, said during the ... toughest year for our turnaround,” CEO Bill Anderson said. The reduction is ...
Bayer chief executive Bill Anderson has followed ... Both will report to pharma division president Stefan Oelrich, who remains in post, as does Christian Rommel, head of pharma R&D, and Holger ...